Aerovate Therapeutics Pre-Tax Income 2020-2025 | JBIO
Aerovate Therapeutics pre-tax income from 2020 to 2025. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Aerovate Therapeutics Annual Pre-Tax Income
(Millions of US $) |
| 2024 |
$-70 |
| 2023 |
$-75 |
| 2022 |
$-51 |
| 2021 |
$-23 |
| 2020 |
$-10 |
| 2019 |
$-3 |
Aerovate Therapeutics Quarterly Pre-Tax Income
(Millions of US $) |
| 2025-03-31 |
$-3 |
| 2024-12-31 |
$-5 |
| 2024-09-30 |
$-16 |
| 2024-06-30 |
$-25 |
| 2024-03-31 |
$-23 |
| 2023-12-31 |
$-20 |
| 2023-09-30 |
$-20 |
| 2023-06-30 |
$-19 |
| 2023-03-31 |
$-17 |
| 2022-12-31 |
$-15 |
| 2022-09-30 |
$-14 |
| 2022-06-30 |
$-12 |
| 2022-03-31 |
$-11 |
| 2021-12-31 |
$-8 |
| 2021-09-30 |
$-6 |
| 2021-06-30 |
$-6 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-4 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.010B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
